Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Cash flows from operating activities:
Net Loss	$ (37,162,827)	$ (36,502,316)
Adjustments to reconcile net loss to net cash used in operations:
Depreciation	388,401	348,339
Amortization of discount and debt issuance costs on long-term debt	3,518,356	4,598,089
Amortization of discount on mandatory redeemable Series B preferred stock	852,869	0
Change in fair value of Convertible Note and loss on conversion to common stock	1,064,817	0
Change in fair value of warrant liability	15,369,253	(2,683,470)
Dividends for mandatory redeemable Series B preferred stock paid in common stock	1,166,771	0
Stock-based compensation	1,979,998	1,059,582
Write down of inventory	694,448	2,488,100
Gain on divestiture	(3,655,000)	0
Investment received from license of intellectual property	(12,194,800)	0
Loss on sale of fixed assets	19,367	28,645
Effects of changes in operating assets and liabilities:
Accounts and lease receivable	76,163	1,024,366
Inventory	41,022	(399,774)
Prepaid expenses and deposits	(4,367,928)	(1,328,461)
Accounts payable and accrued liabilities	(3,502,682)	2,399,877
Warranty liability	(1,056,905)	6,916,209
Accounts payable, related parties	0	(54,914)
Customer deposits	(103,000)	351,595
Net cash used in operating activities	(36,871,677)	(21,754,133)
Cash flows from investing activities:
Capital expenditures	(2,005,498)	(23,222)
Net proceeds received on divestiture	3,655,000	0
Proceeds from sale of fixed assets	5,000	4,800
Net cash provided by (used in) investing activities	1,654,502	(18,422)
Cash flows from financing activities:
Proceeds from notes payable	5,854,140	0
Payments on notes payable	(5,854,140)	(5,750,000)
Proceeds from issuance of mandatory redeemable Series B preferred stock	25,000,000	0
Proceeds from issuance of Convertible Note	38,950,000	0
(Repayment) proceeds, Duke financing obligation	(1,340,700)	1,340,700
Proceeds from long-term debt	0	17,800,000
Payments on long-term debt	(10,000,000)	(9,891,378)
Loan issuance costs	0	(792,221)
Proceeds from issuance of common stock	5,928,235	16,418,662
Proceeds from exercise of warrants and options	35,306	90,065
Net cash provided by financing activities	58,572,841	19,215,828
Change in cash, cash equivalents and restricted cash	23,355,666	(2,556,727)
Cash, cash equivalents, and restricted cash beginning balance	1,512,750	4,069,477
Cash, cash equivalents, and restricted cash ending balance	24,868,416	1,512,750
Interest paid	7,193,613	1,128,470
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents	1,512,750	1,512,750
Conversion of accounts payable		298,350
Marathon
Warrants to purchase common stock		$ 965,747
Arosa
Warrants to purchase common stock	$ 3,540,542